Sai Parenterals Ltd vs Vaishali Pharma Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Sai Parenterals Ltd is ₹ 489.35 as of 05 May 15:30 . The P/E Ratio of Sai Parenterals Ltd is 0 as of March 2023 .The P/E Ratio of Vaishali Pharma Ltd is 0 as of March 2023 . The Market Cap of Sai Parenterals Ltd is ₹ 0 crore as of March 2023 .The Market Cap of Vaishali Pharma Ltd is ₹ 0 crore as of March 2023 . The Revenue of Sai Parenterals Ltd is ₹ 0 crore as of Jun '25 .The Revenue of Vaishali Pharma Ltd is ₹ 24.59 crore as of Jun '25 . The EBITDA of Sai Parenterals Ltd is ₹ 0 crore as of Jun '25 .The EBITDA of Vaishali Pharma Ltd is ₹ 2.21 crore as of Jun '25 . The Net Profit of Sai Parenterals Ltd is ₹ 0 crore as of Jun '25 .The Net Profit of Vaishali Pharma Ltd is ₹ 1.28 crore as of Jun '25 . The Dividend Payout of Sai Parenterals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Vaishali Pharma Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Sai Parenterals Ltd

Sai Parenteral's Limited was originally incorporated as Sai Parenteral's Private Limited', a Private Limited Company on January 12, 2001, with the Registrar of Companies, at Hyderabad.
Thereafter, Company was converted into a Public Limited Company and the name of Company was changed to Sai Parenteral's Limited' w.e.f January 17, 2022. Sai Parenteral's is a diversified pharmaceutical formulations company engaged in the business of Branded Generic Formulations and Contract Development and Manufacturing Organization (CDMO) products and services for the domestic and international markets.
Company has developed a comprehensive and diversified portfolio of complex pharmaceutical products, covering both high-value and high-volume categories addressing critical therapeutic needs across the multiple disease areas.

About Vaishali Pharma Ltd

Vaishali Pharma Limited was originally incorporated as a Private Limited Company with the name 'Vaishali Pharma Private Limited' on 25th, April 2008.
On July 01, 2008 the Company acquired the business of proprietorship concerns of its Promoter Mr. Atul Vasani viz.
M/s.
Vaishali Pharmachem through Business Assignment agreement.
Consequently, the business of said Proprietorship Firm merged into Vaishali Pharma Private Limited.

FAQs for the comparison of Sai Parenterals Ltd and Vaishali Pharma Ltd

Which company has a larger market capitalization, Sai Parenterals Ltd or Vaishali Pharma Ltd?

Market cap of Sai Parenterals Ltd is 2,161 Cr while Market cap of Vaishali Pharma Ltd is 100 Cr

What are the key factors driving the stock performance of Sai Parenterals Ltd and Vaishali Pharma Ltd?

The stock performance of Sai Parenterals Ltd and Vaishali Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Sai Parenterals Ltd and Vaishali Pharma Ltd?

As of May 5, 2026, the Sai Parenterals Ltd stock price is INR ₹489.35. On the other hand, Vaishali Pharma Ltd stock price is INR ₹7.73.

How do dividend payouts of Sai Parenterals Ltd and Vaishali Pharma Ltd compare?

To compare the dividend payouts of Sai Parenterals Ltd and Vaishali Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.